Table 1.
Clinical Characteristics of Patients in the Training, Testing, and Validation Sets
| Characteristics | Training Set | Testing Set | Validation Set |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Age | |||
| ≤60 years | 74 (59.7) | 79 (63.2) | 54 (60.7) |
| >60 years | 50 (40.3) | 46 (36.8) | 35 (39.3) |
| Gender | |||
| Female | 23 (18.5) | 22 (17.6) | 13 (14.6) |
| Male | 101 (81.5) | 103 (82.4) | 76 (85.4) |
| Immunotype | |||
| Type A | 92 (74.2) | 92 (73.6) | 28 (31.5) |
| Type B | 32 (25.8) | 33 (26.4) | 61 (68.5) |
| Tumor size | |||
| ≤3 cm | 53 (42.7) | 41 (32.8) | – |
| >3 cm | 71 (57.3) | 84 (67.2) | – |
| pTNM stage | |||
| I | 18 (14.5) | 20 (16.0) | 7 (7.9) |
| II | 45 (36.3) | 34 (27.2) | 55 (61.8) |
| III | 61 (49.2) | 71 (56.8) | 27 (30.3) |
| Tumor grade | |||
| G1/G2 | 103 (83.1) | 92 (73.6) | 60 (67.4) |
| G3 | 21 (16.9) | 33 (26.4) | 20 (22.5) |
| Gx | 0 (0.0) | 0 (0.0) | 9 (10.1) |
| LVI | |||
| Negative | 38 (30.6) | 44 (35.2) | – |
| Positive | 86 (69.4) | 81 (64.8) | – |
Note: The data of tumor size and LVI were not available in the validation set (TCGA cohort).